drugset / Trial / NCT05193721
A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2024-06-30
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-1901 | Unknown | 0.1 mg/kg | — |
| Subject | SHR-1901 | Unknown | 0.3 mg/kg | — |
| Subject | SHR-1901 | Unknown | 1 mg/kg | — |
| Subject | SHR-1901 | Unknown | 3 mg/kg | — |
| Subject | SHR-1901 | Unknown | 10 mg/kg | — |